通过免疫组织化学对HER2-阳性和不明确乳腺癌的遗传改变
Yi-Fang Tsai1,2,3, Chih-Yi Hsu3,4, Yun-Ning Chiu1,5
1Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, 112201, Taiwan.
Breast cancer (Dove Medical Press)
|March 18, 2025
概括
与HER2 IHC2+/ISH+瘤相比,HER2 IHC3+乳腺癌显示出更高的ERBB2放大和更低的MYC/CCND3放大. 这一发现有助于开发针对HER2阳性乳腺癌的向治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- HER2阳性乳腺癌是一种异质性疾病.
- 免疫组织化学 (IHC) 和现场杂交 (ISH) 用于分类HER2状态.
- 了解与不同HER2 IHC评分相关的遗传变化对于治疗选择至关重要.
研究的目的:
- 识别和比较乳腺癌患者的基因变异,具有不同的HER2免疫组织化学 (IHC) 评分.
- 研究HER2 IHC3+和HER2 IHC2+/ISH+瘤之间特定基因放大频率的差异.
主要方法:
- 分析了120名患有HER2阳性乳腺癌的患者队列.
- 瘤被分为IHC 3+和IHC 2+/ISH+组.
- 使用Thermo Fisher TMO测定进行了全面的分子分析.
- 两组的基因变异被用费舍尔的精确测试来比较.
主要成果:
- 在IHC3+组 (94.4%) 与IHC2+/ISH+组 (45.2%) 相比,观察到ERBB2放大频率显著更高.
- 相反,IHC3+组的MYC放大频率 (10.1%) 和CCND3放大频率 (0%) 与IHC2+/ISH+组相比显著较低 (分别为25.8%和9.7%).
结论:
- 与IHC2+/ISH+瘤相比,HER2 IHC3+瘤的ERBB2放大率较高,CCND3和MYC放大率较低.
- 这些独特的分子形状表明,在这些HER2阳性乳腺癌亚组中,患者的治疗策略不同.
- 这些发现有助于针对HER2阳性乳腺癌的个性化治疗方法.
更多相关视频
03:55Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens
Published on: July 12, 2024
1.2K
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
54
相关概念视频
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...